… - Nucleic Acids . LCA10 is a severe inherited retinal dystrophy associated with mutations in the CEP290 gene. … process by which QR-110 was identified as a potentially optimal therapeutic candidate using a patient-derived retinal … suggest the pharmacodynamic, pharmacokinetic and safety properties make QR-110 a promising candidate for the …
… at NACFC on October 27 Noreen Henig, M.D., Chief Development Officer of ProQR and John P. Clancy, M.D., … QR-010 is designed to be self-administered via an optimized eFlow ® Nebulizer (PARI Pharma GmbH). eFlow ® is a … orphan drug designation in the United States and the European Union. The QR-010 project has received funding from …
… Therapeutics, will present on June 20, 2024 at 2:00pm ET: “Developing Axiomer RNA Editing Technology Towards Clinical Development” This presentation will provide an overview of ProQR’s proprietary ADAR-mediated Axiomer RNA editing technology …
… “QR-1123 aims to block expression of the toxic mutated rhodopsin protein in the retina thereby targeting the … RHO ) gene. The trial will include single-dose escalation (open label) groups and multiple-dose escalation … function and retinal structure will be assessed through ophthalmic endpoints such as visual acuity, visual field and …
… Board. Dr. Dryja will play a key strategic role in the development and advancement of ProQR’s growing ophthalmology pipeline. LEIDEN, The Netherlands, Nov. 09, …
… (FDA) for its molecule QR-010 that is in clinical development for the treatment of patients with CF due to the … CFTR function, the nasal potential difference (NPD). This open label 28-day study enrolls 16 CF patients, 8 homozygous (carrying two copies) for the ΔF508 mutation and 8 compound heterozygous …
… pigmentosa (adRP) due to the P23H mutation in the rhodopsin ( RHO ) gene. ODD provides a special status for … ) gene. The trial will include a single-dose escalation (open label) arm and a multiple-dose (double-masked) arm in … of visual function and retinal structure through ophthalmic endpoints such as visual acuity (BCVA), visual …
… pigmentosa (adRP) due to the P23H mutation in the rhodopsin (RHO) gene. P23H is the most prevalent mutation … gene. The trial will include a single-dose escalation (open label) arm and a multiple-dose (double-masked) arm in … of visual function and retinal structure through ophthalmic endpoints such as visual acuity (BCVA), visual …
… Presentations”. About PQ-110-001 trial PQ-110-001 is an open-label trial that has been designed to enroll … six adults (≥ 18 years) who have LCA10 due to one or two copies of the p.Cys998X mutation in the CEP290 gene. Patients … of visual function and retinal structure through ophthalmic endpoints such as visual acuity, full field …